Pacific Biosciences of California Inc
PACB
Company Profile
Business description
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
Contact
1305 O’Brien Drive
Menlo ParkCA94025
USAT: +1 650 521-8000
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
485
Stocks News & Analysis
stocks
Lower production and higher prices for ASX hydrocarbon play
Improving pricing offsets severe weather impact on sales volumes.
stocks
Alphabet returns on AI investments accelerating
AI propels business across aegments, cloud is grightest; Increasing our fair value.
stocks
We lift our fair value estimate for this ASX energy play
Strong oil and LNG prices are a major win, though we don’t think they will stay high in the long term.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,880.70 | 10.20 | 0.11% |
| CAC 40 | 8,072.13 | 31.96 | -0.39% |
| DAX 40 | 23,954.56 | 63.70 | -0.27% |
| Dow JONES (US) | 48,861.81 | 280.12 | -0.57% |
| FTSE 100 | 10,213.11 | 119.68 | -1.16% |
| HKSE | 25,849.54 | 262.30 | -1.00% |
| NASDAQ | 24,673.24 | 9.44 | 0.04% |
| Nikkei 225 | 59,213.05 | 704.41 | -1.18% |
| NZX 50 Index | 12,903.31 | 133.01 | 1.04% |
| S&P 500 | 7,135.95 | 2.85 | -0.04% |
| S&P/ASX 200 | 8,659.10 | 18.90 | 0.22% |
| SSE Composite Index | 4,113.45 | 5.93 | 0.14% |